QBECO and gut-derived SSI postbiotics for MASLD
preclinicalresearch program · high · Thu Jan 01 2026 00:00:00 GMT+0000 (Coordinated Universal Time)
Improve liver steatosis, inflammation, and fibrosis in obesity-associated metabolic dysfunction-associated steatotic liver disease without weight loss.
Preclinical mouse studies using biweekly subcutaneous injections of inactivated gut bacteria-derived SSI postbiotics, including QBECO from Escherichia coli and QBPMI from Proteus mirabilis.
2026 publication reported QBECO and QBPMI effects in obese mice with MASLD.
QBECO lowered liver mass, triglycerides, macrophages, eosinophil peroxidase activity, and collagen content without altering food intake or body mass; QBPMI also lowered markers of steatosis, inflammation, and fibrosis, while QBKPN did not alter MASLD.
QBKPN SSI for immune function and respiratory infection risk in older adults
phase 2drug program · high · Tue Apr 11 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Test whether QBKPN SSI can improve innate immune function in older adults, reduce respiratory and other infections, improve COVID-19 vaccine response, maintain or improve quality of life, activity level, and health status, and affect glycemic control.
Clinical trial of QBKPN Site Specific Immunomodulator in older adults.
Clinical trial record published for older-adult immune function and respiratory infection study.
QBKPN SSI for older-adult immune function and respiratory infection prevention
exploratorydrug program · high · Tue Apr 11 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Improve immune function in older adults, protect against respiratory and other infections, improve COVID-19 vaccine response, maintain or improve quality of life, activity level, health status, and assess glycemic control effects.
Clinical study of QBKPN Site Specific Immunomodulator.
Clinical trial record published describing QBKPN SSI testing in older adults.
QBKPN SSI for older-adult immune function and respiratory infections
phase 2drug program · high · Tue Apr 11 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Improve innate immune function in older adults, reduce respiratory and other infections, assess COVID-19 vaccine response, quality of life, activity level, health status, and glycemic control.
Clinical study of QBKPN site-specific immunomodulator administered to older adults.
ClinicalTrials.gov study NCT05421325 published April 11, 2023 for older adults and respiratory tract infection endpoints.
Site Specific Immunomodulator platform
exploratoryplatform · high · Mon Mar 30 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Restore or train innate immune function in targeted organ niches for cancer, chronic inflammatory diseases, metabolic disease, infections, and diseases of aging.
Subcutaneously administered inactivated bacterial species selected for association with specific organ niches to mobilize innate immune effector cells to sites of pathology.
Company lists SSI pipeline programs including QBECO, QBKPN, QBSAU, PERIOP-06, and SSI/CAR T combination work.
Publications report that distinct inactivated bacterial-based immune modulators vary in therapeutic efficacy depending on the organ site of pathology and the selected microbial stimulus.
Site Specific Immunomodulators platform
exploratoryplatform · high · Wed Jan 01 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Restore or train innate immune function for cancer, chronic inflammatory, metabolic, infectious, and aging-related diseases.
Subcutaneously administered inactivated bacterial-based immunomodulators selected by organ/site relationship to pathology.
Platform listed in company pipeline and supported by 2020 Scientific Reports publication comparing organ-site-dependent SSI efficacy.
Preclinical studies suggest distinct bacterial-based immune modulators vary in therapeutic efficacy depending on the organ site of pathology.
QBECO SSI for Crohn's disease
phase 2drug program · high · Mon Jun 25 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Induce clinical and/or endoscopic response and remission in patients with moderate to severe Crohn's disease.
QBECO site-specific immunomodulator evaluated in staged clinical trials, including lead-in, randomized placebo-controlled induction, and maintenance components.
Phase 2 QBECO-CD-02 trial designed to enroll a 20-patient lead-in and a 150-patient main study in moderate to severe Crohn's disease.
Earlier clinical publication describes a novel microbial-based immunotherapy approach for Crohn's disease; trial record states the later study builds on past experience with QBECO SSI.
QBECO SSI for ulcerative colitis
exploratorydrug program · high · Mon Jan 01 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Evaluate safety, tolerability, compliance, mechanism of action, and efficacy for induction of clinical response and remission in moderate to severe ulcerative colitis.
Open-label, dose-ranging exploratory clinical study of QBECO site-specific immunomodulation.
Clinical trial in moderate to severe ulcerative colitis published on ClinicalTrials.gov with July 1, 2015 listed date.
A 2018 publication reports gut microbe-based immune stimulation reduced disease pathology and improved barrier function in ulcerative colitis models.
Lung microbial-derived immunotherapy research program
preclinicalresearch program · medium · Sun Jan 01 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Investigate bacterial-derived or microbe-based immunotherapy for lung anti-cancer activity and inflammatory airway disease.
Preclinical studies of bacterial-derived immunotherapy in lung cancer-related innate effector function, cigarette smoke-induced lung inflammation, and allergic airway disease models.
Publications reported in 2016 and 2017 for allergic airway disease, cigarette smoke-induced lung inflammation, and lung anti-cancer effector function models.
Reported attenuation of inflammatory profiles in allergic airway disease and cigarette smoke-induced lung inflammation models, and harnessing of innate lung anti-cancer effector functions with bacterial-derived immunotherapy.
Microbial-based immunotherapy for lung inflammation and allergic airway disease
preclinicalresearch program · medium · Sun Jan 01 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Attenuate inflammatory pathology in lung and airway disease models.
Microbial-based or bacterial-derived immune modulation tested in preclinical models of cigarette smoke-induced lung inflammation and allergic airway disease.
Publications reported in 2016 and 2017 for allergic airway disease and cigarette smoke-induced lung inflammation models.
Published studies report attenuation of inflammatory profiles or immune pathology in mouse models of allergic airway disease and cigarette smoke-induced lung inflammation.
QBKPN SSI healthy volunteer dose-escalation program
phase 1drug program · high · Thu Sep 01 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Assess safety and pharmacodynamics of single and multiple doses of QBKPN SSI in healthy adult volunteers.
Single- and multiple-dose dose-escalation study with subcutaneous QBKPN SSI administration.
Clinical trial record describes healthy-volunteer dose-escalation evaluation.
QBKPN SSI healthy-volunteer dose evaluation
phase 1drug program · high · Thu Sep 01 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Assess safety and pharmacodynamics of single and multiple subcutaneous doses of QBKPN SSI in healthy adult volunteers.
Single and multiple dose-escalation clinical study in healthy volunteers.
ClinicalTrials.gov study NCT02897999 published September 1, 2016.
QBKPN SSI for non-small cell lung cancer
exploratorydrug program · high · Mon Dec 01 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Evaluate safety, tolerability, compliance, and mechanism of action in subjects with second primary pre-invasive or invasive adenocarcinoma after resection of Stage 1 non-small cell lung cancer.
Exploratory clinical study of QBKPN site-specific immunomodulator in NSCLC subjects.
ClinicalTrials.gov study NCT02256852 published December 1, 2014.
A related lung cancer publication reports harnessing innate lung anti-cancer effector functions with a bacterial-derived immunotherapy.
Gut-derived SSI postbiotics for MASLD
preclinicalresearch program · high
Improve liver steatosis, inflammation, and fibrosis in obesity-associated metabolic dysfunction-associated steatotic liver disease.
Biweekly subcutaneous injections of inactivated gut bacteria-derived SSI postbiotics, including QBECO and QBPMI, in obese mice with MASLD.
2026 publication reports preclinical MASLD results for QBECO, QBPMI, and QBKPN comparators.
QBECO lowered liver mass, triglycerides, macrophage markers, eosinophil peroxidase activity, and collagen content without altering food intake or body mass; QBPMI also lowered MASLD markers, while QBKPN did not alter MASLD.
Microbial-based SSI programs for inflammatory lung disease
preclinicalresearch program · medium
Attenuate inflammatory pathology in lung disease models including cigarette smoke-induced lung inflammation and allergic airway disease.
Microbial-based immunomodulator treatment in mouse models of lung inflammation and allergic airway disease.
2016 and 2017 publications report preclinical lung inflammation and allergic airway disease findings.
Publications report attenuation of inflammatory profiles and immune pathology in mouse lung disease models.
PERIOP-06 study in late-stage colon cancer
phase 2drug program · medium
Evaluate a Qu Biologics clinical-stage program in late-stage colon cancer.
Phase 2 clinical study listed by the company as underway.
Company description states a Phase 2 PERIOP-06 study is underway in late-stage colon cancer.
QBECO SSI for late-stage colon cancer liver-metastasis surgery
phase 2drug program · high
Evaluate QBECO SSI in late-stage colon cancer patients undergoing surgery for liver metastasis.
Phase 2 clinical trial of QBECO Site Specific Immunomodulator in the perioperative oncology setting.
Company site identifies the PERIOP-06 Phase 2 trial as running.
QBECO SSI for perioperative late-stage colon cancer
phase 2drug program · high
Evaluate QBECO SSI in late-stage colon cancer patients undergoing surgery for liver metastasis.
Phase 2 clinical trial of QBECO Site Specific Immunomodulator.
PERIOP-06 Phase 2 trial is listed as running in the company site analysis.
QBSAU SSI program
undiscloseddrug program · low
Develop a listed Qu Biologics SSI pipeline program; specific indication and objectives are not provided in the supplied material.
Site-specific immunomodulator program listed in the company pipeline.
Listed in the company pipeline list supplied in the site analysis.
SSI/CAR T combination program
preclinicalresearch program · low
Combine site-specific immunomodulation with CAR T approaches; specific target, indication, and study design are not provided in the supplied material.
Combination research program involving SSI and CAR T therapy.
Listed as an SSI/CAR T combo in the company pipeline list supplied in the site analysis.
